Prevalence of combined contraceptive vaginal rings in Norway

被引:2
|
作者
Skipenes, Vanja Poppe [1 ]
Skjeldestad, Finn Egil [1 ]
机构
[1] UiT, Fac Hlth Sci, Dept Community Med, Res Grp Epidemiol Chron Dis, N-7037 Tromso, Norway
关键词
Contraception; contraceptives; female; healthcare provider; hormonal; vaginal rings; women health; NUVARING(R); EXPERIENCE;
D O I
10.1111/aogs.12942
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction. Little is known about vaginal ring (VR) prescribers and user patterns in Norway and internationally. With data from the Norwegian Prescription Database, we explore user and prescriber characteristics of women initiating VR use. Material and methods. In a cross-sectional study design, we analyzed 47 127 first-time VR users from 1 January 2006 to 31 December 2012. Follow up ended on 30 June 2013. We applied strict definitions for switching from any other hormonal contraceptive before and at the end of VR use. All analyses were performed using SPSS, with chi-squared test, t-test, and survival analysis. Results. At study end, the prevalent use of VR reached 10 per 1000 women of fertile age, which amounted to 3% of all hormonal contraceptive use. The number of first-time VR users increased from 2006 to 2008 only among women under the age of 20. Nearly three out of four new users discontinued after 3 months. Physicians without specialist status and general practitioners accounted for over 70% of the prescriptions, whereas gynecologists accounted for 17% of the prescriptions. Gynecologists were significant prescribers of VR to women aged 35 or more. Conclusions. Gynecologists are important providers of VR to first-time users above 30 years of age. When prescribing VR to first-time users, it is important to discuss the need for contraception in a longer time perspective. Authorizing public health nurses/midwives as VR prescribers to teenagers, from 1 March 2006, may explain the relative increase in VR usage at a younger age.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 50 条
  • [31] Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis
    van Vliet, Huib A. A. M.
    Rosendaal, Frits R.
    Fleischer, Kathrin
    Rosing, Jan
    Helmerhorst, Frans M.
    [J]. CONTRACEPTION, 2010, 81 (01) : 88 - 89
  • [32] THE EFFECTS OF A COMBINED CONTRACEPTIVE VAGINAL RING RELEASING ETHINYLESTRADIOL AND 3-KETODESOGESTREL ON VAGINAL FLORA
    DAVIES, GC
    FENG, LX
    NEWTON, JR
    DIEBEN, TOM
    COELINGHBENNINK, HJT
    [J]. CONTRACEPTION, 1992, 45 (05) : 511 - 518
  • [33] The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring
    Roumen, FJME
    Boon, ME
    vanVelzen, D
    Dieben, TOM
    Bennink, HJTC
    [J]. HUMAN REPRODUCTION, 1996, 11 (11) : 2443 - 2448
  • [34] The combined contraceptive vaginal ring (NuvaRing): evaluation of the clinical and pharmacological evidence
    Gruber, Christian J.
    [J]. WOMENS HEALTH, 2006, 2 (03) : 351 - 356
  • [35] The combined contraceptive vaginal ring, NuvaRing®:: an international study of user acceptability
    Novák, A
    de la Loge, C
    Abetz, L
    van der Meulen, EA
    [J]. CONTRACEPTION, 2003, 67 (03) : 187 - 194
  • [36] Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring
    Timmer, CJ
    Mulders, TMT
    [J]. CLINICAL PHARMACOKINETICS, 2000, 39 (03) : 233 - 242
  • [37] The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism:: a comparative study
    Tuppurainen, M
    Klimscheffskij, R
    Venhola, M
    Dieben, TOM
    [J]. CONTRACEPTION, 2004, 69 (05) : 389 - 394
  • [38] The combined contraceptive vaginal ring, NuvaRing®, and tampon co-usage
    Verhoeven, CHJ
    Dieben, TOM
    [J]. CONTRACEPTION, 2004, 69 (03) : 197 - 199
  • [39] VAGINAL ADMINISTRATION OF A COMBINED ORAL-CONTRACEPTIVE CONTAINING NORETHISTERONE ACETATE
    SOUKA, AR
    KAMEL, M
    EINEN, MA
    SALEH, F
    SALLAM, H
    [J]. CONTRACEPTION, 1985, 31 (06) : 571 - 581
  • [40] Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition
    Mulders, TMT
    Dieben, TOM
    [J]. FERTILITY AND STERILITY, 2001, 75 (05) : 865 - 870